Filter
2291
Filtered Results: 2291
Text search:
clinical
trials
Featured
Recommendations
240
New Publications
396
Language
Document type
No document type
1162
Guidelines
435
Studies & Reports
382
Manuals
103
Fact sheets
84
Strategic & Response Plan
56
Training Material
28
Situation Updates
14
Resource Platforms
12
Infographics
11
Brochures
2
Videos
2
Countries / Regions
India
112
Global
95
South Africa
53
Kenya
39
Western and Central Europe
39
Africa
38
Uganda
25
East and Southern Africa
25
Latin America and the Carribbean
25
Ethiopia
24
West and Central Africa
24
Sierra Leone
22
Russia
22
Nigeria
20
Zambia
20
Brazil
20
Liberia
18
Nepal
18
Malawi
18
Tanzania
17
Ukraine
17
Eastern Europe
17
Rwanda
16
Philippines
15
Zimbabwe
14
Germany
14
Indonesia
14
Ghana
13
Middle East and North Africa
13
Bangladesh
11
Mozambique
11
Namibia
11
South–East Asia Region
11
Congo, Democratic Republic of
10
Asia
10
Guinea
9
South Sudan
8
Peru
8
USA
7
Cameroon
7
Eastern Europe and Central Asia
7
Burkina Faso
6
Eswatini/ Swaziland
6
Botswana
6
Angola
6
Lesotho
6
Cambodia
5
Colombia
5
Chile
5
Albania
5
Thailand
4
Sudan
4
North America
4
United Kingdom
4
Senegal
3
Guinea-Bissau
3
Haiti
3
Syria
3
China
3
Argentina
3
Paraguay
3
Vietnam
3
Spain
3
Mali
2
Côte d’Ivoire / Ivory Coast
2
Pakistan
2
Iraq
2
Lebanon
2
Burundi
2
Myanmar / Burma
2
Sri Lanka
2
Laos
2
Tajikistan
2
Estonia
2
Georgia
2
France
2
Portugal
2
Morocco
1
Saudi Arabia
1
Jordan
1
Afghanistan
1
Turkey
1
Egypt
1
Chad
1
Ireland
1
Singapore
1
Benin
1
Ecuador
1
Greece
1
Madagascar
1
Yemen
1
Western Pacific Region
1
Other region
1
Southern Africa
1
Canada
1
Bulgaria
1
Moldova
1
Iran
1
Kyrgyzstan
1
Kazakhstan
1
Jamaica
1
Denmark
1
Tunisia
1
Authors & Publishers
Publication Years
Category
Countries
562
Clinical Guidelines
353
Public Health
154
Women & Child Health
136
Key Resources
37
Pharmacy & Technologies
34
Capacity Building
21
Toolboxes
COVID-19
305
Mental Health
291
HIV
236
TB
187
NCDs
96
NTDs
94
AMR
72
Ebola
62
Pharmacy
59
Caregiver
57
Rapid Response
56
Disability
27
Planetary Health
24
Global Health Education
22
Refugee
18
Polio
13
Conflict
13
Cholera
11
Zika
11
Health Financing Toolbox
8
Natural Hazards
4
Social Ethics
4
Specific Hazards
2
The method, entitled “elicit-provide-elicit”, is a patient centred method which is adaptable to a range of clinical situations. Recent clinical trial... show that the introduction of advanced communication skills based on this method in general practice allows primary care physicians to prescribe significantly less antibiotics while maintaining a high degree of patient satisfac-tion, without impacting patient recovery time and consultation times.
As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 ... trials. In this review, 46 therapeutic options are examined. The Pan American Health Organization (PAHO) is continually monitoring ongoing research on any possible therapeutic options. As evidence emerges, then PAHO will immediately assess and update its position, and particularly as it applies to any special sub-group populations such as children, expectant mothers, those with immune conditions, etc.
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical ... in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. ... trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large mul-
ticenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical ... in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported serious adverse events (SAEs).
Human African trypanosomiasis (HAT), or sleeping sickness, is a painful and protracted disease transmitted through the bite of infected tsetse flies and it is found in rural parts of sub-Saharan Africa. Sleeping sickness has two clinical phases but ...
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those ...
Medicines and Allied Substances [No. 3 of 2013 47 | An Act to continue the existence of the Pharmaceutical Regulatory Authority and re-name it as the Zambia Medicines Regulatory Authority; provide for the functions and powers of the Authority; provide for the registration and regulation of pharmacie...
This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing ... trials testing the efficacy and safety of several medicines for COVID-19, as of the date of this document, there is a lack of quality evidence to demonstrate chloroquine and/or hydroxychloroquine are effective in the treatment of COVID-19. Evidence is recently emerging via small studies with sub-optimal methodologies that are conflicting.
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) h...
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public health problem throughout Latin America. Current therapeutic options are characterised by limited efficacy, long treatment regimens and frequent toxic side-effects. Advances in this area have been compromised by gaps...
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-cli... development, and operational challenges of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM...
Diabetes mellitus (DM) is a global epidemic with significant morbidity. Diabetic
retinopathy (DR) is the specific microvascular complication of DM and affects 1 in 3 persons with DM. DR remains a leading cause of vision loss in working adult populations. Patients with severe levels of DR are report...
The article from the African Journal of Thoracic and Critical Care Medicine provides updated guidelines on endoscopic lung volume reduction (ELVR) for treating advanced emphysema, a severe form of chronic obstructive pulmonary disease (COPD), which is prevalent in South Africa and other low- and mid...
Background
Noncommunicable diseases are major contributors to morbidity and mortality worldwide. Modifying the risk factors for these conditions, such as physical inactivity, is thus essential. Addressing the context or circumstances in which physical activity occurs may promote physical activity a...
Two decades of epidemiological research shows that silent cerebrovascular disease is common and is associated with future risk for stroke and dementia. It is the most common incidental finding on brain scans. To summarize evidence on the diagnosis and management of silent cerebrovascular disease to ...
Human African trypanosomiasis (HAT), also called sleeping sickness, is a parasitic infection that almost invariably progresses to death, unless treatment is provided. HAT caused devastating epidemics during the 20th century. Thanks to sustained and coordinated efforts during the past 15 years the nu...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for...
